Monday, November 28, 2011


Antiviral Activity

Used in the treatment of HIV-1 infection in combination with at least two additional antiretroviral agents
Active against susceptible HIV strains

Pregnancy Risk Factor

Category C


Hypersensitivity to stavudine or to any of its components
HIV-infected mothers should not breast-feed in order to avoid transmission to a non-infected newborn
Do not use in the presence of bone marrow depression
Use caution in the presence of impaired liver/renal function
Use caution in the presence of peripheral Neuropathy, lactic acidosis/severe hepatomegaly with Steatosis

Mechanism of Action

Inhibits viral DNA synthesis by causing DNA chain termination because stavudine lacks the 3'-hydroxyl group necessary for DNA elongation
Also inhibits cellular DNA polymerase beta and gamma, and markedly reduces the synthesis of mitochondrial DNA


Not elucidated yet in humans
1.25 hours
Renal (40%)


Children : 

< 30 kg of body weight: 1 mg/kg PO q12h 30-60 kg of body weight:  30 mg PO bid Adults:   < 60 kg of body weight: 30 mg PO bid   ³ 60 kg of body weight: 40 mg PO bid Dosage In Renal Failure Creatinine clearance (ml/min): 10-25: 20 mg PO q24h (15 mg if less then 60 kg) 26-50: 20 mg PO q12h (15 mg if less then 60 kg) >50: unchanged
Hemo: 20 mg q24h (³60 kg) or 15 mg q24h (<60 kg)

No comments:

Post a Comment